Status:
COMPLETED
Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Anxiety Disorders
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This study will test the efficacy, safety and tolerability of XBD173 in the treatment of generalized anxiety disorder in patients.
Eligibility Criteria
Inclusion
- Current doctor's diagnosis of generalized anxiety disorder
- In need of psychiatric treatment
- Willingness to complete all aspects of the study
Exclusion
- Current doctor's diagnosis of major depression
- History of schizophrenia or schizoaffective disorders
- Drug dependence within 2 months prior to study start
- For detailed information on eligibility, please contact the study center nearest to you (see below), or call 1-862-778-8300, or visit the following website:
- www.novartisclinicaltrials.com
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
End Date :
May 1 2006
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT00108836
Start Date
March 1 2005
End Date
May 1 2006
Last Update
May 20 2010
Active Locations (23)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigational Site
Anaheim, California, United States, 92801
2
Investigational Site
Los Angeles, California, United States, 90024
3
Investigational Site
Newport Beach, California, United States, 92660
4
Investigational Site
Redlands, California, United States, 92374